All In Biotech

Drug Trial Radar · NCT01231620

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza

Last checked: Nov 20, 2026Latest source record: Oct 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

626

Actual

Start

Jan 15, 2011

Primary completion

Mar 18, 2015

Study completion Mar 18, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.

Conditions

  • Influenza, Human

Interventions

  • ZanamivirDrug

    Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.

  • Placebo to match zanamivirDrug

    Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.

  • OseltamivirDrug

    Oseltamivir will be provided as over-encapsulated 75 mg capsules.

  • Placebo to match oseltamivirDrug

    Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical Response (TTCR) in Participants With Confirmed InfluenzaTime frame: Up to 42 days

Locations

170 sites in 28 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    Escondido, California

  • GSK Investigational Site

    Fullerton, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Oceanside, California

  • GSK Investigational Site

    Aurora, Colorado

  • GSK Investigational Site

    Stamford, Connecticut

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Sunrise, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Idaho Falls, Idaho

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Oak Park, Illinois

  • GSK Investigational Site

    Peoria, Illinois

  • GSK Investigational Site

    Council Bluffs, Iowa

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Royal Oak, Michigan

  • GSK Investigational Site

    Troy, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Valhalla, New York

  • GSK Investigational Site

    Asheville, North Carolina

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Bismarck, North Dakota

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Toledo, Ohio

  • GSK Investigational Site

    Bethlehem, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Roanoke, Virginia

  • GSK Investigational Site

    Marshfield, Wisconsin

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.